ERBB2 and gastroesophageal junction adenocarcinoma: Recent phase 3 trials revealed that chemotherapy with zolbetuximab considerably prolonged overall survival (OS) compared with chemotherapy as first-line chemotherapy in HER2-negative patients with CLDN18.2 expression of unresectable GC or GEJ adenocarcinoma [8,9].